Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA HONOR AWARDS: TYLENOL TAMPERING INVESTIGATION GROUP

Executive Summary

FDA HONOR AWARDS: TYLENOL TAMPERING INVESTIGATION GROUP is one of 36 groups or individuals receiving FDA's "Award of Merit," the agency's highest honor award. The Tylenol tampering group, which consists of five investigators from the Baltimore, Dallas, Philadelphia and San Juan districts, was given the award for "unique and exceptional investigation and reporting of a manufacturing and distribution system as a follow-up to a tampering emergency." The Tylenol group was among many groups and individuals to be acknowledged at the July 10 awards ceremony for their efforts against tampering. FDA Ohio District Office Research Center Director Frederick Fricke, for example, received an HHS "Distinguished Service Award" for "leadership and outstanding scientific achievements in the application of elemental analysis to the forensic evaluation of product tampering cases." P-A President James Cope, Young, Rubicam's Arthur Klein and the Council on Family Health's Frazier Cheston received a "Commissioner's Special Citation" award for their roles in developing a public service announcement on "Simple Precautions Against Tampering." The tampering radio spot began airing in August 1986 ("The Pink Sheet" Aug. 11, T&G-4). In addition to tampering, AIDS drug review, the Action Plan, and Reye Syndrome work were highlighted among the 200-plus FDA awards. FDA's OTC division received a "Group Recognition Award" for "sustained high performance, resourcefulness, and dedication in preparation of monographs for regulation of the OTC industry in the U.S." FDA's Office of Public Affairs received the same award for "exemplary public service on health hazard fronts alerting America's consumers of a record number of product recalls and tamperings in a timely fashion." Awards issued by PHS included a "Superior Service Award" to FDA Center for Drugs and Biologics Acting Director Paul Parkman, MD, "for exceptional management and leadership of the Center's . . . AIDS biologics program and effective participation on the PHS AIDS Task Force," and an "Outstanding Unit Citation" to FDA Virology Division Director Gerald Quinnan, MD, and "Special Recognition" awards to Biological IND Division Acting Director Donald Burlington, MD, and Division of Biometrics' William Fairweather, PhD, for their "outstanding effort[s] in conducting an epidemiologic study which helped resolve the Reye Syndrome controversy and significantly reduced the incidence of the disease." FDA Commissioner Young also received a PHS "Commissioned Corps Meritorious Service Medal" for "Exceptional achievement in leading the FDA to significant improvements in protecting the Nation's public health. Deputy Commissioner Norris was given an FDA "Award of Merit" for "exceptional dedication and contributions to the public health of the Nation, both from a national and international perspective."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel